Edgewise Therapeutics (EWTX) reported a second-quarter 2026 net loss of $57.3 million, or $0.53 per share, compared with a net loss of $36.1 million, or $0.34 per share, in the same period of 2025.
The company said cash, cash equivalents and marketable securities were approximately $460.7 million as of June 30, 2026. That balance excludes $1.55 billion in upfront cash proceeds from the July 2026 sale of sevasemten and its muscular dystrophy business to Servier.
- Research and development expenses were $47.5 million, up from $33.6 million a year earlier.
- General and administrative expenses were $14.4 million, compared with $9.1 million in the prior-year quarter.
- Edgewise completed the Servier transaction for $1.55 billion upfront and up to $1.1 billion in milestone payments.
- The company reported positive top-line data from the 12-week Phase 2 CIRRUS-HCM trial of EDG-7500 in obstructive and nonobstructive HCM.
- Edgewise expects to initiate a Phase 3 EDG-7500 trial in the fourth quarter of 2026 and a Phase 2 EDG-15400 trial in HFpEF in the second half of 2026.
$EWTX Insider Trading Activity
$EWTX insiders have traded $EWTX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $EWTX stock by insiders over the last 6 months:
- ALAN J RUSSELL (Chief Scientific Officer) has made 0 purchases and 2 sales selling 200,000 shares for an estimated $7,881,401.
- JOANNE M. DONOVAN (CMO) has made 0 purchases and 6 sales selling 121,588 shares for an estimated $4,210,201.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$EWTX Hedge Fund Activity
We have seen 89 institutional investors add shares of $EWTX stock to their portfolio, and 84 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 823,828 shares (+12.6%) to their portfolio in Q1 2026, for an estimated $25,950,582
- UBS GROUP AG removed 805,948 shares (-38.1%) from their portfolio in Q1 2026, for an estimated $25,387,362
- ALLIANCEBERNSTEIN L.P. added 685,999 shares (+66.2%) to their portfolio in Q1 2026, for an estimated $21,608,968
- MORGAN STANLEY removed 664,853 shares (-22.8%) from their portfolio in Q1 2026, for an estimated $20,942,869
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 571,855 shares (-36.3%) from their portfolio in Q1 2026, for an estimated $18,013,432
- SOLEUS CAPITAL MANAGEMENT, L.P. added 539,915 shares (+59.3%) to their portfolio in Q1 2026, for an estimated $17,007,322
- QUBE RESEARCH & TECHNOLOGIES LTD added 529,702 shares (+178.8%) to their portfolio in Q1 2026, for an estimated $16,685,613
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
